At the European Society for Medical Oncology (ESMO) Conference 2018 in Munich, Genomic Health announced data showing its Oncotype DX genomic test causes changes to treatment recommendations and substantially reduces the number of chemotherapy referrals for early stage, hormone receptor-positive, HER-2-negative breast cancer patients.

Genomic Health’s ESMO 2018 presentation was based on two studies carried out in Ireland, Italy and France.

The study in Ireland assessed the impact of the genomic test on treatment decisions during routine clinical practice for node positive (N+) breast cancer. Results of the test significantly impacted the treatment advice that healthcare professionals gave to patients in 64% of cases and caused a 27% reduction in chemotherapy recommendations.

The second study in France and Italy involved both N+ and node negative (N0) patients. The results from the Oncotype Dx changed treatment advice for 35% of patients and there was net reduction in chemotherapy recommendations of 43%.

Oncotype Dx produces a breast recurrence score based on patient’s genomic code helping clinicians to determine the best treatment option for patients.

Head of the breast cancer unit of Bethesda Hospital, Germany, Professor Ulrike Nitz said: “These new results show the unique value of adding genomic information provided by the Oncotype DX test to better target chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Oncotype DX identifies patients who can safely be spared chemotherapy toxicity and side effects. Furthermore, we have to be concerned about a relevant proportion of patients who seem to be undertreated if the risk of recurrence is evaluated using only traditional clinical parameters.

“The use of the Oncotype DX test allows us to tailor treatment plans more accurately to suit the needs of individuals, and to use resources more effectively.”

These results support previous data from the TAILORx trial, which showed the utility of the genomic test to determine the benefit of chemotherapy treatment on specific patients

Genomic Health UK managing director Steve Ogram said: “There is a wealth of evidence from around the world to demonstrate that the Oncotype DX test is a crucial tool in guiding decisions on clinical care for breast cancer patients.

“Over the summer, the world’s biggest adjuvant breast cancer treatment trial – TAILORx – drew on 10,000 cases to definitively confirm that Oncotype DX is the only test that reduces both under-treatment and overtreatment with chemotherapy.”